Artivion (NYSE:AORT) Announces Earnings Results, Beats Expectations By $0.03 EPS

Artivion (NYSE:AORT) posted its quarterly earnings data on Thursday. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.03, FiscalAI reports. Artivion had a positive return on equity of 5.98% and a negative net margin of 2.16%.The business had revenue of $118.30 million for the quarter, compared to analysts’ expectations of $116.42 million. The company’s quarterly revenue was up 19.2% on a year-over-year basis.

Here are the key takeaways from Artivion’s conference call:

• Artivion delivered a strong 2025 financial year with adjusted constant-currency revenue up 13%, Adjusted EBITDA up 26%, positive free cash flow for the year, and net leverage down to 1.8x.
• Commercial momentum was broad-based: Q4 stent graft revenue grew 36% and On‑X grew 24%, with management focused on bringing additional European stent graft products to the U.S. and Japan to expand TAM.
• Key regulatory/clinical milestones are progressing—AMDS reported favorable 2‑year data and the company filed the final PMA module targeting FDA approval in mid‑2026, while NEXUS one‑year IDE data were strong and remain on track for H2‑2026 approval.
• Near‑term headwinds include a $2.3M Italian payback adjustment recorded for 2019–2025, softer tissue processing performance (full‑year tissue revenue down), lingering cybersecurity impacts on comparables, and an expected R&D increase (~100 bps) and elevated CapEx (~$50M) in 2026.
• 2026 guidance (excluding any Endospan acquisition) calls for 10%–14% constant‑currency growth, Adjusted EBITDA of $105M–$110M and slightly positive free cash flow, while the potential Endospan deal or additional PMA wins represent upside not included in the outlook.

Artivion Price Performance

Shares of AORT traded down $2.65 during midday trading on Friday, hitting $38.00. 217,310 shares of the company traded hands, compared to its average volume of 322,470. Artivion has a one year low of $21.97 and a one year high of $48.25. The firm has a market cap of $1.80 billion, a P/E ratio of -160.96 and a beta of 1.59. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.93 and a quick ratio of 2.88. The stock has a 50-day moving average of $43.76 and a 200-day moving average of $42.75.

Insider Activity at Artivion

In other news, insider John E. Davis sold 6,394 shares of the business’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $45.17, for a total transaction of $288,816.98. Following the completion of the transaction, the insider directly owned 198,842 shares in the company, valued at $8,981,693.14. The trade was a 3.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Jean F. Holloway sold 7,315 shares of the company’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $45.30, for a total transaction of $331,369.50. Following the completion of the transaction, the senior vice president directly owned 156,093 shares in the company, valued at approximately $7,071,012.90. The trade was a 4.48% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 128,448 shares of company stock valued at $5,793,361 in the last quarter. 7.60% of the stock is currently owned by company insiders.

Institutional Trading of Artivion

Several institutional investors and hedge funds have recently made changes to their positions in AORT. Caitong International Asset Management Co. Ltd purchased a new position in shares of Artivion during the third quarter worth approximately $27,000. Smartleaf Asset Management LLC lifted its stake in Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after purchasing an additional 538 shares during the last quarter. Quadrant Capital Group LLC purchased a new stake in Artivion during the third quarter valued at about $92,000. iSAM Funds UK Ltd purchased a new position in shares of Artivion in the third quarter worth about $131,000. Finally, Van ECK Associates Corp lifted its stake in shares of Artivion by 19.0% in the 3rd quarter. Van ECK Associates Corp now owns 3,176 shares of the company’s stock valued at $134,000 after acquiring an additional 506 shares during the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Analyst Ratings Changes

AORT has been the subject of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and set a $58.00 price objective on shares of Artivion in a report on Monday, February 2nd. Canaccord Genuity Group restated a “buy” rating and set a $51.00 price target on shares of Artivion in a research note on Wednesday, December 17th. Wall Street Zen downgraded Artivion from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artivion in a research report on Wednesday, January 21st. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $50.00 price target on shares of Artivion in a research report on Friday, November 7th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Artivion presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.11.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.